Science, medicine and the future: Contraception

British Medical Journal

Volumn 319, Issue 7215, 1999, Pages 969-972

  Baird, David T ^a   Glasier, Anna F ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NHS LOTHIAN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; CONTRACEPTIVE AGENT; FOLLITROPIN RECEPTOR BINDING INHIBITOR; GONADORELIN ANTAGONIST; MALE CONTRACEPTIVE AGENT; METHYLESTRENOLONE; MIFEPRISTONE; PHOSPHODIESTERASE INHIBITOR;

CONTRACEPTION; DRUG DELIVERY SYSTEM; HORMONAL CONTRACEPTION; HUMAN; IMMUNIZATION; LUTEAL PHASE; MEIOSIS; NIDATION; OOCYTE MATURATION; OVARY FOLLICLE; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; SPERMATOGENESIS;

EID: 0033539392     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.319.7215.969     Document Type: Review

References (20)

1. World Health Organisation. Life in the 21st century -a vision for all. In: The world health report. Geneva, WHO, 1998:120.
2. Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use; 25 year follow up of cohort of 16 000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999;318:96-100.
3. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of anti-estrogens. Mol Endocrinol 1995;9:659-69.
4. Glasier A, Thong KJ, Dewar M, Markie M, Baird DT. Comparison of mifepristone and high dose oestrogen-progestogen for emergency postcoital contraception. N Engl J Med 1992;327:1041-4.
5. Baird DT. Potential contraceptive effects of antigestogens. In: Donaldson M, Dorflinger L, Brown SS, Benet LZ, eds. Clinical application of mifepris tone (RU 486) and other antiprogestins. Washington, DC: National Academy Press, 1993:148-83.
6. Gemzell-Danielsson K, Swahn M-L, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod 1993;8:870-3.
7. Rimmer C, Horga M, Cerar V, Alder EM, Baird DT, Glasier A. Do women want a once a month pill? Hum Reprod 1992;7:608-11.
8. Swahn M L, Bygdeman M, Chen JK, Gemzell-Danielsson K, Song S, Yang Q, et al. Once a month treatment with a combination of mifepristone and a prostaglandin analogue misoprostol. Hum Reprod 1999;14:485-8.
9. World Health Organisation. Menstrual regulation by mifepristone plus prostaglandin result from a multicentre trial. Hum Reprod 1995;10:308-15
10. Martin CW. Cross cultural acceptability of hormonal male contraception [abstract]. Acta Obstet Gynecol Scand 1997;167(suppl 76):P72.62.
11. Meriggiola MC, Bremner WJ. Progestin-androgen combination regimens for male contraception. J Androl 1997;18:240-4.
12. Nieschlag E, Weinbauer GF, Behre HM. Male contraception based on testosterone in combination with other agents. In: Bhasin S, Gabelníck HL, Spicler JM, Swerdloff RS, Wang C, Kelly C, eds. Pharmacology, biology and clinical applications of androgens. Current status and future prospects. Proceedings of 2nd international androgen workshop, California, 17-20 February 1995. New York: Wiley-Liss, 1996:395-407.
13. Sundaram K, Kumar N, Bardin CW. 7α methyl-nortesterone (MENT): the optimal anthogen for male contraception. Ann Med 1993;25:199-205.
14. Harrison PF, Rosenfield A, eds. Contraceptive technology and the state of science: new horizons. In: Contraceptive research and development. Washington, DC: National Academic Press, 1996:125-65.
15. Stewart CC, Kaspar P, Brunet LJ, Bhan H, Gadi I. Köntgen C, et al. Blastocyst implantation depends on material expression of leukaemia inhibitory factor. Nature 1992;359:76-9.
16. Lessev BA. The use of integrins for the assessment of uterine receptivity. Fertil Steril 1994;61:812-4.
17. Griffen D, Strategy of vaccíne development. In: Alexander NJ, Griffin PD, Spicler WM, Waites GMH, eds. Gamete interaction: prospects for immunocontraception. New York: Wiley-Liss, 1990:501-22.
18. Alexander NJ. Future contraceptives: vaccines for men and women will eventually join new implants, better spermicides and stronger, thinner, condoms. Sci Am. 1995;273(3):13G-11.
19. Herr JC. Immunocontraceptive approaches. In: Harrison PF, Rosenfield A, eds. Contraceptive research and development. Washington, DC: National Academy Press, 1996:401-29.
20. Baird D. "A fifth freedom." BMJ 1965;ii:1111-8.